Literature DB >> 8620912

An epidemiological investigation of Norwalk virus infection in South Africa.

M B Taylor1, S Parker, W O Grabow, W D Cubitt.   

Abstract

A study was carried out to determine the incidence and seroprevalence of Norwalk virus (NV) in the Pretoria area, South Africa, using a recombinant NV (rNV) immunoassay for the detection of serum IgG antibodies. Maternal antibody was detectable in infants' sera up to approximately 6 months of age. Infection with NV was detected serologically in the second year of life and the seroprevalence of NV IgG rose from 37.1% at 7-11 months of age to 62.1% by the age of 40 years. No significant differences in seroprevalence of NV IgG antibody was evident between subjects of European or African ethnic origin, where overall seroprevalence rates were 56.4% and 53.9% respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620912      PMCID: PMC2271623          DOI: 10.1017/s0950268800052444

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  24 in total

1.  Prevalence of antibody to the Norwalk virus in various countries.

Authors:  H B Greenberg; J Valdesuso; A Z Kapikian; R M Chanock; R G Wyatt; W Szmuness; J Larrick; J Kaplan; R H Gilman; D A Sack
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

2.  The electron microscopical and physical characteristics of small round human fecal viruses: an interim scheme for classification.

Authors:  E O Caul; H Appleton
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

3.  Immunobiology of Norwalk virus.

Authors:  N R Blacklow; J E Herrmann; W D Cubitt
Journal:  Ciba Found Symp       Date:  1987

4.  Norwalk virus genome cloning and characterization.

Authors:  J N Xi; D Y Graham; K N Wang; M K Estes
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

5.  Three serotypes of Norwalk-like virus demonstrated by solid-phase immune electron microscopy.

Authors:  D C Lewis
Journal:  J Med Virol       Date:  1990-01       Impact factor: 2.327

6.  Immune response and prevalence of antibody to Norwalk enteritis virus as determined by radioimmunoassay.

Authors:  N R Blacklow; G Cukor; M K Bedigian; P Echeverria; H B Greenberg; D S Schreiber; J S Trier
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

7.  Acquisition of serum antibody to Norwalk Virus and rotavirus and relation to diarrhea in a longitudinal study of young children in rural Bangladesh.

Authors:  R E Black; H B Greenberg; A Z Kapikian; K H Brown; S Becker
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

8.  Molecular characterisation of small round structured viruses associated with gastroenteritis in South Africa.

Authors:  M Wolfaardt; M B Taylor; W O Grabow; W D Cubitt; X Jiang
Journal:  J Med Virol       Date:  1995-12       Impact factor: 2.327

9.  Enzyme immunoassay using baculovirus-expressed human calicivirus (Mexico) for the measurement of IgG responses and determining its seroprevalence in London, UK.

Authors:  S P Parker; W D Cubitt; X Jiang
Journal:  J Med Virol       Date:  1995-07       Impact factor: 2.327

Review 10.  Laboratory diagnosis of viral gastroenteritis.

Authors:  G M Beards
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

View more
  12 in total

1.  Study of Norwalk virus and Mexico virus infections at Ga-Rankuwa Hospital, Ga-Rankuwa, South Africa.

Authors:  T K Smit; A D Steele; I Peenze; X Jiang; M K Estes
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Broadly reactive nested reverse transcription-PCR using an internal RNA standard control for detection of noroviruses in stool samples.

Authors:  Maria Cristina Medici; Monica Martinelli; Franco Maria Ruggeri; Laura Anna Abelli; Simona Bosco; Maria Cristina Arcangeletti; Federica Pinardi; Flora De Conto; Adriana Calderaro; Carlo Chezzi; Giuseppe Dettori
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  The First Molecular Detection of Aichi Virus 1 in Raw Sewage and Mussels Collected in South Africa.

Authors:  Oikwathaile Onosi; Nicole S Upfold; Michael D Jukes; Garry A Luke; Caroline Knox
Journal:  Food Environ Virol       Date:  2018-12-17       Impact factor: 2.778

Review 4.  Diagnosis of noncultivatable gastroenteritis viruses, the human caliciviruses.

Authors:  R L Atmar; M K Estes
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

5.  Evaluation and validation of real-time reverse transcription-pcr assay using the LightCycler system for detection and quantitation of norovirus.

Authors:  Xiaoli Pang; Bonita Lee; Linda Chui; Jutta K Preiksaitis; Stephan S Monroe
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

6.  Norovirus epidemiology in South African children <5 years hospitalised for diarrhoeal illness between 2009 and 2013.

Authors:  N A Page; M J Groome; S Nadan; R Netshikweta; K H Keddy; B Poonsamy; J Moyes; S Walaza; K Kahn; S A Madhi; M B Taylor; J Mans; C Cohen
Journal:  Epidemiol Infect       Date:  2017-04-10       Impact factor: 4.434

7.  Diverse norovirus genotypes identified in sewage-polluted river water in South Africa.

Authors:  J Mans; R Netshikweta; M Magwalivha; W B Van Zyl; M B Taylor
Journal:  Epidemiol Infect       Date:  2012-03-21       Impact factor: 4.434

Review 8.  Current Status of Norovirus Infections in Children in Sub-Saharan Africa.

Authors:  Samuel Munalula Munjita
Journal:  J Trop Med       Date:  2015-11-16

9.  Prevalence of human calicivirus infections in Kenya as determined by enzyme immunoassays for three genogroups of the virus.

Authors:  S Nakata; S Honma; K Numata; K Kogawa; S Ukae; N Adachi; X Jiang; M K Estes; Z Gatheru; P M Tukei; S Chiba
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

Review 10.  Norovirus Epidemiology in Africa: A Review.

Authors:  Janet Mans; George E Armah; A Duncan Steele; Maureen B Taylor
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.